<DOC>
	<DOCNO>NCT02646358</DOCNO>
	<brief_summary>This open-label study design evaluate effect renal disease pharmacokinetics vepoloxamer relative pharmacokinetics healthy subject normal renal function .</brief_summary>
	<brief_title>Study Effect Renal Impairment Pharmacokinetics Vepoloxamer</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Key Subject must weigh â‰¤ 125 kg body mass index 20 40 kg/m2 Subject must willing confined clinical research unit duration study , 5 day If female , subject must pregnant lactating , negative pregnancy test , agree sexual abstinence , use appropriate birth control method screen 30 day study drug administration If male , subject agree sexual abstinence , surgically sterile , use appropriate birth control method screen 30 day study drug administration Considered Investigator healthy clinically stable respect underlie renal impairment base medical evaluation include vital sign , ECG laboratory test result Nonsmoker , smoke few 10 cigarettes/day Key Exclusion Criteria Uncontrolled medical condition ( treat untreated ) consider clinically significant Investigator Experienced illness consider Investigator clinically significant within 2 week study drug administration Treatment another investigational drug device study within 30 day 5 halflives ( whichever longer ) prior screen Positive test drug abuse and/or positive alcohol test Screening Day 1 Donated lose significant volume blood plasma within 90 day prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>